Lavon et al. [31], demonstrated a moderate sensitivity and specificity in the identification of loss-of-heterozygosity (LOH) and MGMT/PTEN methylation in peripheral blood in patients with gliomas, detecting MGMT methylation in up to 24% of patients. Here, MGMT is linked to central nervous system cancer.